CLRB Profile
Cellectar Biosciences, Inc., headquartered in Florham Park, New Jersey, is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of novel cancer therapeutics. Established in 2002, the company specializes in the discovery of innovative drugs utilizing its proprietary phospholipid drug conjugate (PDC) platform. This platform is designed to enhance the targeted delivery of therapeutic agents to cancer cells, aiming to improve efficacy and reduce off-target effects.
The company's lead product candidate, CLR 131 (iopofosine I-131), is a radiotherapeutic PDC currently undergoing advanced clinical trials. CLR 131 is being evaluated in Phase 2 studies for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies, as well as in a Phase 2B trial for r/r multiple myeloma (MM). Additionally, CLR 131 is in Phase I trials for various pediatric cancers, r/r head and neck cancers, and further r/r MM indications. This investigational drug combines a potent radioisotope with a phospholipid drug conjugate, targeting cancer cells with high precision.
Cellectar Biosciences is also advancing its preclinical pipeline with CLR 1900, another PDC-based chemotherapeutic program aimed at treating solid tumors. This program leverages the company’s proprietary technology to deliver chemotherapeutic agents specifically to tumor cells, potentially increasing therapeutic efficacy and minimizing systemic toxicity. The company’s PDC technology is supported by several collaborative partnerships, including those with Avicenna Oncology GMBH for the CLR 2000 Series, Orano Med for the CLR 12120 Series, IntoCell Inc., and LegoChemBio.
By integrating its advanced PDC technology with collaborative research efforts, Cellectar Biosciences seeks to make significant strides in the treatment of various cancers. The company's focus on targeted therapeutic delivery and its robust clinical pipeline underscore its commitment to developing innovative treatments for challenging cancer indications.
|
